Chemotherapy Administration Guidelines in Neutropenia and Elevated Bilirubin

Patient Assessment and Risk Stratification

The American College of Physicians recommends that patients with an absolute neutrophil count (ANC) below 1,500 cells/mm³ should not proceed with chemotherapy due to increased risk of severe toxicity and infection-related mortality 1, 2
Patients with solid tumors receiving chemotherapy who develop neutropenia are at increased infection risk, particularly when ANC trends downward, with a significant drop from previous counts indicating high risk for further decline 1, 3, 4
Elevated bilirubin is a significant independent risk factor for severe neutropenia in patients receiving irinotecan-based chemotherapy, with bilirubin levels above 0.7 mg/dL substantially increasing this risk 2

The National Comprehensive Cancer Network recommends holding chemotherapy in patients with declining ANC and significantly elevated bilirubin to prevent life-threatening complications 5, 2, 6
Wait until ANC recovers to >1,500 cells/mm³ before resuming chemotherapy, and address and resolve bilirubin elevation to minimize risk of severe hematologic toxicity 1, 2
Consider fluoroquinolone prophylaxis (levofloxacin or ciprofloxacin) if neutropenia is expected to be prolonged (>7 days) to reduce infection risk 3, 4, 7

Monitor patients with neutropenia closely for fever or signs of infection, as they require immediate hospitalization and IV antibiotics if symptoms develop, according to the Infectious Diseases Society of America guidelines 5, 6

The American Society of Clinical Oncology recommends rechecking CBC in 3-7 days to monitor ANC recovery 8
Chemotherapy should be resumed only when ANC recovers to >1,500 cells/mm³, as stated by the Infectious Diseases Society of America 8

Secondary prophylaxis with filgrastim (5 mcg/kg/day subcutaneously) or pegfilgrastim (6 mg once per cycle) should be initiated starting 24 hours after the next chemotherapy dose, as recommended by the American Society of Clinical Oncology 9
Fluoroquinolone prophylaxis (levofloxacin 500 mg daily or ciprofloxacin 500 mg twice daily) should be considered if neutropenia is expected to persist >7 days, according to the Infectious Diseases Society of America 8, 10